Headline Details

Spark's price for Luxturna blindness gene therapy too high: ICER

Published on: Fri, 12 Jan 2018 20:33:57 UTC
News Agency: Reuters
Description:
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

Click here for FULL Story on Reuters

Also happening now

HeadlineNews Agency
Huge Brazil rubbish dump closes after six decades BBC
Cuba, U.S. hold talks on law enforcement despite tensions Reuters
US musician Tom Petty died of 'accidental drug overdose' BBC
France: Emmanuel Macron’s marvellous manoeuvres this week BBC
Mexico ruling party hopeful proposes graft law to boost election campaign Reuters